<SEC-DOCUMENT>0001193125-21-329988.txt : 20211115
<SEC-HEADER>0001193125-21-329988.hdr.sgml : 20211115
<ACCEPTANCE-DATETIME>20211115163853
ACCESSION NUMBER:		0001193125-21-329988
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20211115
FILED AS OF DATE:		20211115
DATE AS OF CHANGE:		20211115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		211411609

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d261201d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated November 15, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><A HREF="d261201dex991.htm">Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC</A></B><A HREF="d261201dex991.htm" > <B>with
 Positive New Data for LAG-3 Therapy, Eftilagimod Alpha</B> </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><A HREF="d261201dex992.htm">IMMUTEP GRANTED CHINESE PATENT FOR eftilagimod alpha, A SOLUBLE LAG-3 FUSION PROTEIN, IN COMBINATION WITH A PD-1
 PATHWAY INHIBITOR</A></B><A HREF="d261201dex992.htm" > </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November 15, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d261201dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Release </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Publishes AIPAC, <FONT
STYLE="white-space:nowrap">TACTI-002</FONT> and <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Trial Posters at SITC </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with
Positive New Data for <FONT STYLE="white-space:nowrap">LAG-3</FONT> Therapy, Eftilagimod Alpha </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>AIPAC </B>poster presentation includes new data and graphs showing: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Very encouraging Overall Survival (OS) data from the abstract published on 9&nbsp;November 2021, including
statistically significant benefit in 3 patient subgroups representing a majority of patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A statistically significant Quality of Life preservation in first 6 months in the eftilagimod alpha
(&#147;efti&#148;) group in total population </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The statistically significant increase in peripheral CD8 T cells in patients in the efti group of the total
population<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> and the statistically significant correlation of this increase with improved OS </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">TACTI-002</FONT> </B>poster presentation of more mature interim data from 2nd
line head and neck squamous cell carcinoma (HNSCC) patients (Part C): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Encouraging Overall Response Rate (ORR), with 29.7% (11/37) of 2nd line HNSCC patients responding to the
combination therapy of efti and pembrolizumab </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Favourable duration and depth of responses, with 5 Complete Responses and a minimum duration of response extended
to &gt; 9 months across all responding patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Responses continue to be seen in <FONT STYLE="white-space:nowrap">PD-L1</FONT> low and high expressors
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Further data from <FONT STYLE="white-space:nowrap">TACTI-002</FONT> is expected to be reported in H1 calendar
year 2022 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">TACTI-003</FONT> </B>is a Phase IIb multicentre, open label, randomised and
controlled, trial enrolling approximately 154 patients with 1st line HNSCC<B></B><B>&nbsp;</B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150;
15</B><B></B><B>&nbsp;November 2021 &#150;</B> Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy
treatments for cancer and autoimmune disease, announces new data has been published in poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 which took place from <FONT STYLE="white-space:nowrap">10-14</FONT>
November 2021 in the US. The new data relates to the Company&#146;s Phase IIb AIPAC trial and Part C of its Phase II <FONT STYLE="white-space:nowrap">TACTI-002</FONT> study (also designated <FONT STYLE="white-space:nowrap">KEYNOTE-798).</FONT> In
addition, a poster presentation of the trial design of the Company&#146;s new randomised Phase IIb study in 1st line HNSCC was also presented at SITC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All three poster presentations relate to Immutep&#146;s lead candidate efti and are available on the Company&#146;s website:
https://www.immutep.com/investors-media/presentations.html. New data which is shown in addition to the data from the abstracts released on 9&nbsp;November 2021 is summarised below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep will present data from the posters in a global webcast for investors on Wednesday, 17&nbsp;November 2021 at 8.00 am AEDT / Tuesday, 16&nbsp;November
2021 at 4.00 pm EST. Details are below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PHASE IIB AIPAC POSTER PRESENTATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the final OS data announced on 10&nbsp;November 2021, Immutep reports new Quality of Life (QoL) data from AIPAC. QoL is a secondary endpoint of
the study. In the total trial population, a statistically significant QoL preservation was observed in the first 6 months in the efti group of patients who were treated with efti in combination with paclitaxel. This compares favourably to the
comparator group (paclitaxel and placebo) where a significant deterioration in these measures were reported at 6 months (see Figure 1). QoL is generally very important for patient compliance and forms part of reimbursement discussions after any
potential marketing approval. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Immune monitoring was conducted on a selection of patients from the total population: N=36/31 comparator
group/efti group. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Figure 1. Quality of Life at 3 and 6 months of treatment (Global Health Status / QoL <FONT
STYLE="white-space:nowrap">QLQC30-B23)</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP> </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g261201g1115110438455.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, the AIPAC trial demonstrates a statistically significant and clinically meaningful OS benefit in
now three prespecified (prior to unblinding) patient subgroups. A majority of patients fall into at least one of the patient subgroups and therefore derive a statistically significant benefit (Table 1). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients under the age of 65 years (representing 66.7% of patients in the efti group) reported a median OS of
22.3 months compared to 14.8 months in the comparator group, indicating an absolute survival benefit of +7.5 months (HR = 0.66; p = 0.017) favoring the efti group (see Figure 2). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients with a low monocyte count (&lt; 0.25/nl) at the commencement of the study (representing 21.9% of
patients in the efti group) reported a median OS of 32.5 months compared to 12.9 months in the comparator group, indicating an absolute survival benefit of +19.6 months (HR = 0.44; p = 0.008) favoring the efti group. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients with a more proliferating tumor cell type expressing more
<FONT STYLE="white-space:nowrap">neo-antigens</FONT> (i.e. leading to more immunogenicity), characterised as luminal B (representing 48.8% of patients in the efti group) reported a median OS of 16.8 months compared to 12.6 months in the comparator
group, indicating an absolute survival benefit of +4.2 months (HR = 0.67; p = 0.049) favoring the efti group. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Figure 2.
Kaplan-Meier curve for OS in patients &lt; 65 years of age </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g261201g1115110438993.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">* Differences are statistically significant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Table 1 &#150; Overall Survival in key patient subgroups at final analysis at 72.5% of events in the
overall population </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Group</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%&nbsp;of&nbsp;patients&nbsp;in<BR>efti group</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Efti group /</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Comparator&nbsp;group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Median&nbsp;OS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(months)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Absolute&nbsp;OS&nbsp;benefit<BR>from efti</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Population</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Efti&nbsp;+&nbsp;paclitaxel<BR>Placebo&nbsp;+&nbsp;paclitaxel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20.4<BR>17.5</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>+2.9&nbsp;months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.88</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.197</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&lt; 65 years </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">66.7</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Efti + paclitaxel<BR>Placebo + paclitaxel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="top" ALIGN="right">22.3<BR>14.8</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>+7.5 months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.66</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.017</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Low monocytes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&lt; 0.25/nl</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">21.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Efti + paclitaxel<BR>Placebo + paclitaxel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="top" ALIGN="right">32.5<BR>12.9</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>+19.6&nbsp;months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.44</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.008</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Luminal </B>B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">48.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Efti + paclitaxel<BR>Placebo + paclitaxel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="top" ALIGN="right">16.8<BR>12.6</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>+4.2 months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.67</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.049</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pleasingly, these results have improved since interim data were reported at the San Antonio Breast Cancer Symposium (SABCS) in
December 2020. A comparison is provided in Table 2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Table 2 &#150; Comparison of interim Overall Survival data and final Overall Survival data
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Group</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Interim&nbsp;data</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(SABCS 20)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Final&nbsp;data</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(SITC 21)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Median OS<BR>improvement<BR>[months]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Population</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>+2.7&nbsp;months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.83</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>+2.9&nbsp;months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.88</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.197</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+0.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&lt; 65 years </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>+7.1 months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.62</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>+7.5 months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.66</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+0.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Low monocytes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&lt; 0.25/nl</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>+9.4 months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.47</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>+19.6&nbsp;months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.44</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.008</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+10.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Luminal B</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>+3.8 months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.69</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.077</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>+4.2 months</B><BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HR = 0.67</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">p = 0.049</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+0.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as briefly reported on 10&nbsp;November 2021, immune monitoring studies showed an increase in peripheral CD8 T
cells in patients from the efti group of the total population (N=36/31 comparator group/efti group).<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> This increase is statistically significant and is also significantly correlated with improved
OS, demonstrating strong <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept.</FONT></FONT> New data and graphs are provided below (see Figures 3 &amp; 4). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Figure 3. Mean &plusmn; SEM of absolute count of CD8 T cells* prior next dosing</I></B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><I>Figure 4. Correlation between cytotoxic CD8 T cells and OS</I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g261201g1115110439880.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g261201g1115110439482.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CEO, Marc Voigt commented: </B>&#147;The combination of the OS data in the prespecified subgroups, immune
monitoring data and Quality of Life data, which were all statistically significant, give us confidence as we move forward with the development of efti in various late-stage settings. The results here are particularly noteworthy because Her2<SUP
STYLE="font-size:85%; vertical-align:top">-</SUP>HR<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> metastatic breast cancer is not a particularly immunogenic tumour and so does not always respond to treatment with modern immunotherapies such
as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. Indeed, we have seen across our various studies that efti, with its unique mechanism of action, has the potential to benefit many cancer patients,
including those with more limited treatment options.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PHASE II <FONT STYLE="white-space:nowrap">TACTI-002</FONT> POSTER PRESENTATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s <FONT STYLE="white-space:nowrap">TACTI-002</FONT> is being conducted in collaboration with Merck&nbsp;&amp; Co., Inc., Kenilworth, NJ, USA
(known as &#147;MSD&#148; outside the United States and Canada). The study is evaluating the combination of efti with MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in 183 patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in 1st and 2nd line (Parts A and B, respectively) or 2nd line head and neck
squamous cell carcinoma (HNSCC, Part C). The results announced today relate to Part C only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CSO and CMO, Dr Frederic Triebel said:</B>
&#147;It is encouraging to see deep and durable responses in low <FONT STYLE="white-space:nowrap">PD-L1</FONT> expressing patients who may not typically respond to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy when given on its own. When given in combination with efti, we are seeing an ORR of about 30%. Results from
<FONT STYLE="white-space:nowrap">TACTI-002</FONT> demonstrate an encouraging ORR combined with a durable response and good safety. This was key to securing Fast Track Designation with the US FDA in April this year.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Findings 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> line HNSCC&#151;Part C </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ORR of 29.7% (11/37) per iRECIST in patients unselected for <FONT STYLE="white-space:nowrap">PD-L1</FONT> on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intention-to-treat</FONT></FONT> basis and 35.5% (11/31) in evaluable patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.5% of patients (5/37) reporting a Complete Response, indicating deep responses </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Median duration of response is not yet reached and none of the patients with a confirmed response progressed
within 9 months </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5 patients still under therapy and 1 patient completed 2 years of therapy </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ORR in patients in the <FONT STYLE="white-space:nowrap">PD-L1</FONT>
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1 (N = 27) and <FONT STYLE="white-space:nowrap">PD-L1</FONT> <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 20 (N = 14) subgroups is 40.7% and 64.3%, respectively </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Table 3 &#150; <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Interim ORR Results for Part C (data <FONT
STYLE="white-space:nowrap">cut-off</FONT> date: 4&nbsp;August 2021) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Part C</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2nd&nbsp;line&nbsp;HNSCC<SUP STYLE="font-size:85%; vertical-align:top">3</SUP></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Tumour Response</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Best Overall
Response (BOR) per iRECIST</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stage 1 &amp; 2</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N (%)</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total
N=37</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete Response (CR)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">5&nbsp;(13.5)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial Response (PR)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">6&nbsp;(16.2)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stable Disease (SD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&nbsp;&nbsp;3&nbsp;(8.1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Progressive Disease (PD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">17&nbsp;(45.9)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not Evaluable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">6&nbsp;(16.2)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Disease Control Rate (DCR)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>14&nbsp;(37.8)</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Objective Response Rate (ORR)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>11&nbsp;(29.7)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ORR in evaluable pts (N=31)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>11&nbsp;(35.5)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusion</B>: The more mature data from 2nd line HNSCC patients continues to be encouraging, including when compared to
historical studies with checkpoint inhibitor monotherapy in comparable patient groups. These results are supportive of Immutep&#146;s randomised Phase IIb <FONT STYLE="white-space:nowrap">TACTI-003</FONT> study in the 1st line HNSCC indication
conducted in collaboration with MSD. The trial design for the new <FONT STYLE="white-space:nowrap">TACTI-003</FONT> study is outlined below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety
(data <FONT STYLE="white-space:nowrap">cut-off</FONT> date 16&nbsp;April 2021) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combination treatment continues to be safe and well tolerated with
no new safety signals reported thus far. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further data from <FONT STYLE="white-space:nowrap">TACTI-002</FONT> are planned to be reported in H1 of calendar year 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PHASE II <FONT STYLE="white-space:nowrap">TACTI-003</FONT> POSTER PRESENTATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-003</FONT> is a Phase IIb multicentre, open label, randomised and controlled, trial enrolling approximately 154 patients
with 1st line HNSCC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients will be enrolled into two cohorts (see Figure 5): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort A (approximately 130 patients) will evaluate the safety and efficacy of efti in combination with
MSD&#146;s KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), compared to pembrolizumab alone in 1st line metastatic or recurrent HNSCC patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive tumours
(CPS <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort B (up to 24 patients) is an experimental arm which will determine the efficacy and safety of efti plus
pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumours (CPS &lt; 1). </P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As assessed by local investigator read. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Figure 5. <FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial design </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g261201g1115110440418.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pembrolizumab will be given at a dose of 400 mg via intravenous infusion on day 1 of each
<FONT STYLE="white-space:nowrap">6-week</FONT> treatment cycle (maximum of 18 infusions). Efti will be subcutaneously injected at a dose of 30 mg every 2 weeks for the first 6 months (4 cycles) and thereafter at a dose of 30 mg every 3 weeks for up
to 2 years in total. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study is ORR according to RECIST 1.1. and iRECIST will be used for treatment decisions. Secondary
endpoints include OS and Progression Free Survival (PFS). The <FONT STYLE="white-space:nowrap">TACTI-003</FONT> study is open for patient recruitment in the US and Ukraine, with further clinical sites expected to be opened in the coming months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GLOBAL WEBCAST </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date&nbsp;&amp; Time:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.00 am AEDT (Sydney) Wednesday 17&nbsp;November 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.00 pm EST (New York) Tuesday 16&nbsp;November 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10.00 pm CET (Berlin) Tuesday 16&nbsp;November 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Register:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">https://fnn.webex.com/fnn/onstage/g.php?MTID=ef12af93633b5d17a2e4e176fcac2f070</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Questions:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investors are invited to submit questions in advance via <U>immutep@citadelmagnus.com</U>.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A replay of the webcast will also be available at <U>www.immutep.com</U> from the day after the event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AIPAC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Active Immunotherapy Paclitaxel (AIPAC) is a multicentre, placebo-controlled, double-blind, 1:1 randomised&nbsp;Phase IIb clinical trial in HER2-negative/HR
positive metastatic breast cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study is evaluating the combination of efti with paclitaxel chemotherapy. 227 HER2-negative/HR positive metastatic
breast cancer patients are randomised 1:1 to a chemo-immunotherapy arm (efti plus paclitaxel) or to a comparator arm (placebo plus paclitaxel). Patients receive weekly paclitaxel at days 1, 8 and 15, with either efti or placebo injected
subcutaneously on days 2 and 16 of each <FONT STYLE="white-space:nowrap">4-week</FONT> cycle, repeated for 6 cycles. Thereafter, patients pass over to the maintenance phase with efti alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information regarding the AIPAC trial, visit clinicaltrials.gov (identifier: NCT02614833)
and&nbsp;<U>https://www.ncbi.nlm.nih.gov/pubmed/30977393</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TACTI-002</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-002</FONT> (Two ACTive Immunotherapies) is being conducted in collaboration with Merck&nbsp;&amp; Co., Inc., Kenilworth,
NJ, USA (known as &#147;MSD&#148; outside the United States and Canada). The study is evaluating the combination of efti with MSD&#146;s KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in up to 183 patients with
second line head and neck squamous cell carcinoma or <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer in first and second line. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
trial is a Phase II, Simon&#146;s <FONT STYLE="white-space:nowrap">two-stage,</FONT> <FONT STYLE="white-space:nowrap">non-comparative,</FONT> open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT> multicentre clinical study that is taking
place in study centres across Australia, Europe, the UK and US. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients participate in one of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part A - first line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), <FONT
STYLE="white-space:nowrap">PD-X</FONT> naive </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part B - second line NSCLC, <FONT STYLE="white-space:nowrap">PD-X</FONT> refractory </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part C - second line head and neck squamous cell carcinoma (HNSCC), <FONT STYLE="white-space:nowrap">PD-X</FONT>
naive </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-002</FONT> is an <FONT STYLE="white-space:nowrap">all-comer</FONT> study in terms of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC. <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression is typically reported in three groups
for NSCLC: &lt; 1%, <FONT STYLE="white-space:nowrap">1-49%</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50% (Tumour Proportion Score or TPS) and in HNSCC: &lt; 1, <FONT STYLE="white-space:nowrap">1-19</FONT> and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 20 (Combined Positive Score or CPS). Patients with a high <FONT STYLE="white-space:nowrap">PD-L1</FONT> status are typically more responsive to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy such as pembrolizumab, whereas those with low <FONT STYLE="white-space:nowrap">PD-L1</FONT> status are overall less responsive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information about the trial can be found on Immutep&#146;s website or on ClinicalTrials.gov (Identifier: NCT03625323). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme Corp., a subsidiary of
Merck&nbsp;&amp; Co., Inc., Kenilworth, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TACTI-003</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-003</FONT> is a Phase IIb clinical trial in first line head and neck squamous cell carcinoma (HNSCC) in collaboration
with Merck&nbsp;&amp; Co., Inc., Kenilworth, NJ, USA, known as &#147;MSD&#148; outside the United States and Canada. It will evaluate efti in combination with MSD&#146;s KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(pembrolizumab) as a first line therapy in unresectable recurrent or metastatic HNSCC patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative and <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (CPS
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1) tumours. It will be a randomised, controlled clinical study in approximately 154 first line HNSCC patients and will take place across Australia, Europe and the US in up to 35 clinical sites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study will evaluate the safety and efficacy of efti in combination with pembrolizumab, compared to
pembrolizumab alone in first line metastatic or recurrent HNSCC patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (CPS <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1) tumours (cohort A), and determine the efficacy and safety of
efti plus pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumours (CPS &lt; 1) (cohort B). According to the current plans, about 130 patients in cohort A will be randomised 1:1 to receive either efti plus
pembrolizumab or pembrolizumab alone. Subjects in cohort B (up to 24 patients) will receive a combination of efti and pembrolizumab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint
of the study is the Overall Response Rate (ORR) according to RECIST 1.1. and iRECIST will be used for treatment decisions. Secondary endpoints include OS and Progression Free Survival (PFS). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is
eftilagimod alpha (efti or IMP321), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT
STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies for immune response modulation, are being developed by Immutep&#146;s large
pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 12, 95 Pitt Street, Sydney NSW 2000
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d261201dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g261201dsp38.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Release </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP GRANTED CHINESE
PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE <FONT STYLE="white-space:nowrap">LAG-3</FONT> FUSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROTEIN, IN COMBINATION WITH A <FONT
STYLE="white-space:nowrap">PD-1</FONT> PATHWAY INHIBITOR </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 15</B><B></B><B>&nbsp;November 2021 &#150;</B> Immutep Limited
(ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy treatments for cancer and autoimmune disease, is pleased to
announce the grant of a new patent (number ZL 201680005401.3) entitled &#147;Combined Preparations for the Treatment of Cancer or Infection&#148; by the Chinese Patent Office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This new Chinese patent follows the grant of the corresponding European and United States patents announced in 2018 through 2021. The claims of the new patent
protect Immutep&#146;s intellectual property relating to combined therapeutic preparations comprising (a)&nbsp;its lead active immunotherapy candidate eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), which is a soluble <FONT
STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> and (b)&nbsp;an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibody. The claims are also directed to use of the preparations for the manufacture of a medicament for the treatment of cancer and infectious disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new patent is owned by Immutep S.A.S. and exclusively licensed to Immutep&#146;s partner in China, EOC Pharma (&#147;EOC&#148;). The patent expiry date is
8&nbsp;January 2036. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CEO, Marc Voigt, noted: &#147;This new patent again highlights the important investments Immutep is making to protect efti,
with its unique mode of action. The <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune checkpoint has attracted significant interest from the medical, pharma and investment communities in recent months following important validation of this target
by the pharma industry. We are well placed to make an important contribution to this exciting field and are also very much looking forward to continuing our close collaboration with EOC Pharma as they commence multiple trials with efti in China in
the coming months.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EOC Pharma CEO, Xiaoming Zou, said: &#147;We are again very pleased that our partner, Immutep, continues to make progress in
building a robust patent estate around efti. This underpins our continued investment in developing this promising candidate for the Chinese market.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About efti in China </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is exclusively licensed to EOC
Pharma for the territory of Greater China (namely mainland China, Hong Kong S.A.R, Macao S.A.R. and Taiwan). Under its agreement with Immutep, EOC will make further milestone payments to the Company if efti achieves specific development milestones,
as well as pay sales-based royalties. Immutep retains the rights to efti outside the territory of Greater China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About EOC Pharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EOC Pharma is an integrated biopharmaceutical company focusing on the discovery, research, development and commercialisation of innovative oncology products.
With an insight-driven strategy and integrated business platform, EOC Pharma strives to build a portfolio of products with strategic synergies from independent R&amp;D and licensing and enrich the product pipeline with first- and best <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-in-class</FONT></FONT> oncology drugs to benefit the millions of patients who currently have limited access to high quality oncology treatments in China. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 12, 95 Pitt
Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g261201dsp38.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g261201dsp30.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble <FONT
STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC)
activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products,
including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is listed on the
Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website
<U>www.immutep.com</U> or by contacting: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim
McCarthy, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g261201dsp30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g261201dsp30.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MRF\OA\';]:19QGA*T\30:O<-JS3?9BASYLFX%LC&.?K0!VU !0 4 % !0 4
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M>UGQ-J5MJLUE:K& C!5(3+'(%92FT[(YJM><9.**+^(?$5IB2X5@F?\ EI
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1GI@#UH W* "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g261201dsp38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g261201dsp38.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M8_\ 7$_SJ<)\++S+XX^ATO@+_D4K;_??_P!"-<^)_B,[L!_ 7S_,Z6N<[0H
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g261201g1115110438455.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g261201g1115110438455.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K -,# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF2RI!"\LK!(T4LS'H
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MWJ7[G?HLPSGS<$\>FWCG\<5GZ%K.HIH5DHT>9L$[B"<;,GD<=?:NOK,\/?\
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MU*$^RW8MR#\V8@^[]>*IZ;IE[I\<,)U+S;>(8V&  G\<UZ!B:M%%% !1110
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M&Q) 4,NW(SGK\XQ^-::3122/&DJ,\9PZJP)7ZCM0%SF_L'C3_H.Z3_X+G_\
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4]0HHHH- HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g261201g1115110438993.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g261201g1115110438993.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Q /T# 2(  A$! Q$!_\0
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M / AO_B*/,U/_GVL_P#P(;_XBKM% %+S-3_Y]K/_ ,"&_P#B*/,U/_GVL_\
MP(;_ .(J[10!2\S4_P#GVL__  (;_P"(H\S4_P#GVL__  (;_P"(J[10!2\S
M4_\ GVL__ AO_B*/,U/_ )]K/_P(;_XBIKRV:[MFA6YGMR?^6D! 8?3((_2L
MO_A'IO\ H8-8_P"_L?\ \10!>\S4_P#GWL__  (;_P"(J&>^N[;9YZZ?%O;:
MF^Z*[CZ#*<FJ%UX9FEAV_P#"0ZL/F!^:6/'7_<J74;#3([:RBU:^DD$<A\M[
MAQEV((^;  ./RH MS7MY;A3,EA&&. 6N6&3_ -\4])]1D4,D-DRGH5N6(_\
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MGIC':I?NN_0WBU73C;WNGG;H=31115G*%%%% !1110 444V3=Y3[/O[3M^M
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M@@ ZDGH*9I^JVVIF3[/O^3'++@,#T8>H.#^5 ":("-'M@6+$+R3WJ_5#1O\
MD$V_^[5^@ HHHH *1E5T9'4,K#!!&012T4 <)?:/#I'C&V?2,:<UQ;%(UCA
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MT46I)TY>;^=CIJ***LYP[52TK_D#V7_7!/\ T$5=[52TK_D#V7_7!/\ T$4
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g261201g1115110439482.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g261201g1115110439482.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #% 3L# 2(  A$! Q$!_\0
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MG#<<U%2?)%RM>W8<5=V+5%(N[8N_&['..F:6K0@HHHH **** "BBB@ HHHH
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MDL(@=E0 M&!C;],5?    & . * %HHHH **** "BBB@ HHHH **** "BBB@
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MTR.YM6B#.\D;%0<G@XX["@#-\.R*GA/4[JPN'EBBNY9)[J8%_MBA5RP ']W
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M@D%CR02":U:* *NGZ;::5:_9K*$11;BQ&222>Y)Y)^O8 =JXGPE_R5[XB_\
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1HS110 9HS110 9HS110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g261201g1115110439880.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g261201g1115110439880.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "V 1(# 2(  A$! Q$!_\0
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M=@"V"\AW!A&!_=4MFLC5?&VMQ:IJ-U:S6Z66FW=K:_8C!EKH2[<ONSD?>^7
M[<T >G5E^)/^16U?_KRF_P#0#7"CQMKAUH77F0FQ.N'2/[/$ WA0#^\WYSGC
M)&,8-;'BGQ88](UBR_X1[7FQ;S1^>MF#$?E(W;MWW>^: +WPX_Y)QX?_ .O&
M/_T&NHKE_AQ_R3CP_P#]>,?_ *#744 %%%% !1110 4444 %%%% !7':OXZL
M;5KRRDM9RR*R%AC'2NQKQ'Q."=;U' _B;^5)L\C-\95PL(RI.UV=/X9\>V,&
M@6%M]DN&8)M!R.>37HL;^9$CX(W*#@]J^>] !^QZ?QV'\Z^@X?\ 41_[H_E0
MF3E6,K8B=15'>VWXCZ***9[(4444 %<[%_R4.X_[!J_^C*SOB#=W-I9VIM[B
M6$ESDQN5SQ[5Y>NK:C_PD<C_ &^ZW_9%&[SFSC?]:5SR,5F\,/5E2<6['T'1
M7)> +JXNM(G>XGEF82X!D<L1Q[UUM,]##5U7I1JI6N%%%%!N%%%% "4444 +
M1110!P&NSZCJ&K31QW.H+I<AC\R-+.Y1MJ;BT:E8_P"-MN7!R%! %=3X9AN+
M?PW8Q74ADF6,!F,;)^&& /'J0">M<=XBL18^(H\:# =.9E+/;Z<DS,I1][.<
M$J0VS' '/)/..R\-+=)X<L5O;:*VN!$-\42A57\!D#Z XH =?^'=%U6[AN]0
MTJSNKB'_ %<LT*LR_B13I] T>ZU2'4Y]+M);Z$8CN'A4NOI@XS6C10!G?V!I
M UC^UQIEI_:)&/M7DKYG_?76F>)/^16U?_KRF_\ 0#6I67XD_P"16U?_ *\I
MO_0#0!E_#C_DG'A__KQC_P#0:ZBN7^''_)./#_\ UXQ_^@UU% !114%W>6]C
M;M<7,@CB7JQ!/\J!2DHJ[T1F7_B./3[Z*TDTW4'>9RD31QJ5<@9.#N_GBM>&
M0RPK(8WC+#.QP,CZXKB=;\3Z++KF@R)?(5CG<L=C<?+]*ZFPUS3=4D:.RNA*
MZC) 4C _$4&4<31DTHS3;\T:%%%%!L%%%% !7AWBFWBN->O5F0.HE/!)KW&O
M$_$7_(P7O_70U+/GN(6U2@UW_0RM.L[:TNHA;PK&-P&%)QUKWZ'_ %$?^Z/Y
M5X/;?\?4/^^/YU[Q#_J(_P#='\J$9</-MU&_+]1]%%%4?3'(^*M+LWU/2)3&
MV^XOD24K(PWK@\'!Z5U<,,=O"D,2[8T&%&>@KG_$Q!OM!Y'_ "$$[^QKHL@]
M#2N@.'^)/_'C9_[Y_E7DZI>C5&N3:)L:$1X\\9'S9STKUCXD_P#'C9_]=#_*
MO.*3W/B<WGRXR>FZ7Y'IWPY_Y MQ_P!=OZ5V5<;\.?\ D"W'_7;^E=E36Q]-
ME7^YT_0****9Z 4444 )1110 M%%% '+:QI]G;ZS/?#7;?3KB\@6&9+E8W#H
MN<;0_(ZG(Z'TK8T&QL]-T.TL["?S[6*,+'+O#;AZY''Y<5R.M)(_C'4/[,:-
M+I;6)KK[3Y2JP^;:5+JQ/&<]%_'-=5X:O4U'P[97D9<K+'N!>-4/Y+Q^7% &
MK17GOQ UN>QU&WM-.\3&SU22+=;V0,*1@[N99GD!PF.,#!..,UCZQXLUB#7[
MXIJ_E7-G=VL%IIJ>7LO(Y-N]\$%FSEB"#QCZT >M5E^)/^16U?\ Z\IO_0#7
MG2^+=:_X2<'^TF-T=<.GG1\1[5M0#^\VXWYX!W9QS72^*-;UU='UBW3PE=O;
MBVF07(O+<*5VGY]I?=C'.,9H N?#C_DG'A__ *\8_P#T&NHKE_AQ_P DX\/_
M /7C'_Z#6SJ>LV>CQ&6],Z1 9:1+>215'3DJIQ0!?KG_ !I_R+%S^%;%G>17
MT FA68(>GFPM&3^# &L?QI_R+%S^%#.7'?[M4]'^1X9?7""_L_EE(BD8N5A<
M@<>H%>C_  U8/J-PRYP8@1D8KBZ[7X<?\A2Y_P"N?]:A'QV6R3Q=)6V_X)Z7
M1115GW8R:&.XA:*:-9(W&&5AD$5R_A;2=/AU#5Y8[*!)(KYUC8(,H,#@>@K>
MO696&TD9KFO#\TGVG6OG/%^_\A7!4QRA)QY=C54FU<[*O$_$7_(P7O\ UT->
MT0$F($G->+^(O^1@O?\ KH:ZXRYXJ7<^9XC5J4/7]"A;?\?4/^^/YU[Q#_J(
M_P#='\J\'MO^/J'_ 'Q_.O>(?]1'_NC^55$QX=_Y>?+]1]1S?ZIJDJ.?_4M4
M5OX<O1GU$=SCO$!/VS0^3_R$$_D:Z:Q),AR<UR.OW.;_ $M4MKR3[/>K)*T=
MK(ZJN#SD+@_A75Z9()0)%#!6&0&4J?Q!Y%>'AU^\@=,]F<Q\2?\ CQL_^NA_
ME7G%>C_$G_CQL_\ KH?Y5YQ7O/<_/,Z_WR7R_(].^'/_ "!;C_KM_2NRKC?A
MS_R!;C_KM_2NRJEL?4Y5_N=/T"BBBF>@%%%% "4444 +1110!YQJPN]1G47-
MI-((040M;SMD9Z\VYY/MQQ7<:,9#H]L9=^_9SO!!_'*J?T%<;K5L+OQ3<V2:
M<9H+6WBV"UTVWD*;MQPS2_F O'7/-=GH\7D:1;1>4\6U,;'C2,CZJGRC\* %
MNM'TR^E\V\TVSN),8WS0*Y_,BIOL5J9HIC;0^;$NV-_+&Y!Z ]A4]% $/V2V
M^U?:OL\7VC;M\W8-^/3/7%4?$G_(K:O_ ->4W_H!K4K+\2?\BMJ__7E-_P"@
M&@#*^'/'PW\/G_IQC_\ 0:B\;:M!#X:OX9KB")VC&U'<*6^8= 3S4OPY_P"2
M;:!_UXQ_^@U>FBCDE)>-&(/!90<5Y^.KSI./*S6G%2N6-,U**[MX?(EBE3:!
MNC8,,X]0:I>-/^18N?PJS9HD<P"(JCT48JMXT_Y%BY_"G@:LZD).3OJ<F914
M<-.W\K_(\?KM?AQ_R%+G_KG_ %KBJ[7X<?\ (4N?^N?]:[%N?#Y7_OE/U/2Z
M***L^^,[4XHYD\J5%>-AAE89!%8]OHVEVDPFMM.M(91T>.%5/Y@5M7_WEJG7
MSN+;5:1UT_A1K6_^I6O&/$7_ ",%[_UT->SV_P#J5KQCQ%_R,%[_ -=#7MT?
MX4?1'RG$G\.'K^A0MO\ CZA_WQ_.O>(?]1'_ +H_E7@]M_Q]0_[X_G7O$/\
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M/$7_ ",%[_UT->SV_P#J5KQCQ%_R,%[_ -=#7N4?X4?1'R?$G\.'K^A0MO\
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MG33"6Y6#[TLC$*6YX)Y&<56A\&F R&/4 K23-*9%@PZ9;<0K!L@?7</:F?\
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MR*5D/FR*54%'",.>>IZ],=Z@/@N+[)>P)>R 744:,Q0$@J[N3U[ESQVI1X/
M^U@W[%9[>X@7]T,H)9-Y/7G!SZ4 ;B:G927ILTNHVN!U0-STSCZXYQZ5;K#M
MO#S6U_!<+>;5BP2L<>QI,)MPY!PP[],^];E !1110 4444 )1110 M%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
9% !1110 4444 %%%% !1110 E%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g261201g1115110440418.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g261201g1115110440418.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (3 FX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_\ $T?\([=_]#'JO_?4?_Q-;]% &!_PCMW_ -#'JO\ WU'_ /$T?\([=_\
M0QZK_P!]1_\ Q-;]% &!_P ([=_]#'JO_?4?_P 31_PCMW_T,>J_]]1__$UO
MU0U76M/T6W$U_<I$IX5>K,?0 <F@#/\ ^$=N_P#H8]5_[ZC_ /B:/^$=N_\
MH8]5_P"^H_\ XFLE_B+"7_<:->R1]G8HF?P)S3?^%B?]0.Z_[^I_C0!L?\([
M=_\ 0QZK_P!]1_\ Q-'_  CMW_T,>J_]]1__ !-8_P#PL3_J!W7_ ']3_&C_
M (6)_P!0.Z_[^I_C0!L?\([=_P#0QZK_ -]1_P#Q-'_".W?_ $,>J_\ ?4?_
M ,36/_PL3_J!W7_?U/\ &C_A8G_4#NO^_J?XT ;'_".W?_0QZK_WU'_\31_P
MCMW_ -#'JO\ WU'_ /$UC_\ "Q/^H'=?]_4_QI\/Q%M=^+O2[VWC_P">@"R
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M_B:WZ* ,#_A';O\ Z&/5?^^H_P#XFC_A';O_ *&/5?\ OJ/_ .)K?HH P/\
MA';O_H8]5_[ZC_\ B:/^$=N_^ACU7_OJ/_XFM^B@# _X1V[_ .ACU7_OJ/\
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MK+V/OZ'->GZ#=&]T&QN&.6>%23[XH T:*** "BBB@ HHHH *P+[_ )';2/\
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M7HNG:- 8K"U2$-]YARS?4GDU?HH **** "BBB@ HHHH **** "BBB@ HHHH
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M>N1VJ6J\/E_:KC;<M(^5W1EP1'QV';- %BBBB@ HHHH **** "BBB@ HHHH
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M_0OG_P #%_PH_P"$OU+_ *%\_P#@8O\ A5.BCZM /K=0N?\ "7ZE_P!"^?\
MP,7_  H_X2_4O^A?/_@8O^%4Z*/JT ^MU"Y_PE^I?]"^?_ Q?\*/^$OU+_H7
MS_X&)_A5.BCZM /K=0N?\)?J7_0OG_P,3_"C_A+]2_Z%\_\ @8G^%4Z*/JT
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M>1%_PD>M?]"\O_@<G^%'_"1ZU_T+R_\ @<G^%2T4>RB'MY$7_"1ZU_T+R_\
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M-<W4=LD$9=_E!!."P.&_ "M^FFGL)Q:W"BBBF26O"O\ R,&J'MY<=:'C$_\
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MBBB@ HHK*UOQ!I^@V_F7<O[QO]7"G+N?8?UHW!M+5FE)+'#&TDCJB*,LS'
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M6+L3^/ ^@KZC 4ZU:A&516?F?.XVK1HU7&#NO(]#^VVG_/S#_P!_!1]MM?\
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MF'_OX*\]_L32O^@=:_\ ?L4?V)I7_0.M?^_8H^JR[A]<CV/0OMMI_P _,/\
MW\%'VVT_Y^8?^_@KSW^Q-*_Z!UK_ -^Q1_8FE?\ 0.M?^_8H^JR[A]<CV/0O
MMMI_S\P_]_!1]MM?^?F'_OX*\]_L32O^@=:_]^Q1_8FE?] ZU_[]BCZK+N'U
MR/8]"^VVO_/S#_W\%*+RV8X%S"2>P<5YY_8FE?\ 0.M?^_8H.AZ41_R#K;\$
MQ1]5EW#ZY'L>DYHKSJWBOM)82:1>2(!UM9W+Q/[<\K]177:'KL.LPN-A@NX3
MB>W<\H?4>H/8UC.E*&YO3JQJ;&E)<P1-MDGC1NN&< TS[=9_\_4'_?P5D^(?
M">F^((F>:W07BC]W<;>01T!]1[5S>FZ1I-S Z7&C6274#F*=1$,;AW'L>M3&
M/-H5.?*KG=?;K/\ Y^X/^_@H^W6?_/U!_P!_!7)?\([HG_0)L_\ OT*/^$=T
M3_H$V?\ WZ%:>Q?<S]NNQUOVZS_Y^H/^_@H^W6?_ #]0?]_!7)?\([HG_0)L
M_P#OT*3_ (1W1/\ H$V?_?H4>Q?</;KL==]NL_\ GZ@_[^"C[=9_\_4'_?P5
MR7_".Z)_T";/_OT*/^$=T3_H$V?_ 'Z%'L7W#VZ['6_;K/\ Y^H/^_@H^W6?
M_/U!_P!_!7)?\([HG_0)L_\ OT*/^$=T3_H$V?\ WZ%'L7W#VZ['6_;K/_GZ
M@_[^"C[=9_\ /U!_W\%<E_PCNB?] FS_ ._0H_X1W1/^@39_]^A1[%]P]NNQ
MUOVZS_Y^H/\ OX*5;RU=@JW,+,>@$@)-<C_PCNB?] FS_P"_0IK>&]$92/[+
MM5SW1-I'T(Y%'L7W#VZ[';T5R_A^]GLK]M%O)GF79YEG-(<LR#JA/<K_ "KJ
M*R:L[&R::N@HHHI#"L"^_P"1VTC_ *];C^:5OU@7W_([:1_UZW'\TH WZ***
M "D/W3]*6D/W3]* ,/P;_P BG8_1_P#T-JW:PO!O_(IV/T?_ -#:MV@ HHHH
M *BG\_"^0(R=PW;\_=[XQWJ6JUX8-D?GS-$/,7:58KEL\#\?2@"S1110 444
M4 %9.M^'K#7K<1W<>)%_U<R</&?8_P!*UJ*$[":3T9XWK6A:AX>EQ>#SK0G"
M7:#CZ./X3^E4.HR*]PEBCFB:.5%=&&&5AD$5Y]K_ ("DMB]WH0W1]7LF/_H!
M[?0UZ>'Q[7NU?O/(Q66)^]1^XY"BFJX9F4AD=#AT<893Z$4ZO534E='BRBXN
MTD%%%->1(TW.P"CO0VDKL23;LAU3Z=87NLW?V;38?,93B25N(XOJ?7V%;.@^
M#+W6=MQ?B2SL#R$Z2RC_ -E'ZUZ58V%KIMHEK9P)#"@X517F8C'V]VE]Y[&%
MRR_O5ON,;P]X1LM"'GM_I-\1\UPXY'LH_A%=%117EMMN[/:C%15D%1W'_'M+
M_N'^525'<?\ 'M+_ +A_E2&4]$_Y EG_ -<Q57Q//=V^C/):DJ=P#LO4+5K0
M_P#D"6?_ %S%79HDFB>*1=R.,$>HK.K!SIN*=FRZ<E":DU>QYCI]@EW&]Q,\
MK*KA"D*[I"3WY[>]20F#3]1N[<W#(I4HEP@R4.>O'Y<4ZY\WPUJEQ&Q_<E"#
MEMH9#T.?:L:V@N]5.;4&&VSS<R#D_P"X._U-?-4,+4J25.E#WT]3W:V(ITXN
M=67N-:%_5=<,DWV:#=/(Y5E6-,.S@8+#^Z#[TVUT)YV$^JL'YRMLI^0?[Q_B
M/Z5I6&FVVG1E8$^=OOR,<NY]S5NOJL'E5.D_:5?>E^"]#YC%YI.JO9TO=C^+
M]1  J@   < #H*6BBO6/*"BBB@ HHHH **** "BL^>[O&OY+2RB@9H8ED=IF
M(!W9PHQ]#S39-;MH$/G)(LJNT;Q@9*L /T.X 'OD4N9%<K-*BL:;7TMKLQW$
M$D0,:[8W 5RY8C')QC SG-6)M3+:+_:-DBRJ5W@.VT #KGW%',@Y6:-%4[V]
M,%I.]N(I;B*/>8FDQ@>I[U2GUJ2*_M[<1QXE6,X).6WGG!Z#'OUH<D@46S9H
MHHIDA1110 4444 %%%% !52Y:6QN8M5M!^_M_OJ/^6D?=3_,5;HP",'H>#4R
MBI*S+A)PE=':6MS'=VL5Q"VZ.5 RGV-<SJ<7V+Q7'(HQ'?0D-_OKT_2IO!<Q
M&G7-BQYM)RJ_[IY%/\6KL33KD=8KI1^#<5YJ]V1ZLK2@%%'>@=:ZCB,5O$<4
M2&26RNDA)=8Y#M(D*]0,'(_&I'UMX8(I)]-N86G8)"CR1_.2,]=V!^-1IX<M
M5L[B/9&;F8.//*DD;CZ9_E3VT.*"Q6WL8K2/IYJ3Q&2.7 [C.1^%3J5[I=%]
M&ED+JY5[5?XEE'*GTXSG\*C_ +9TW?$GVV'=* 4&>N>GT_&J@T6=-#2PCNPL
MBR;]VU@F,YV  Y"_C56V\+O#:36[W:,) J@K&1@!MWK3U"T2ZWB&R\^2*%O/
M,:@DH>,EMN.:G&MZ859OMT.%8*>3U/0>_P"%9L/ARX%Q"UQ=QO!"@C")&5)4
M9QDYZ\TZ+P],)K62:[C86I58@L9&47)YYZ\TO>':)H7>J?9[D6T-I<7<PC\U
MDAVC8OJ22.3V%5X_$$%Q*B6EM/< HLC%-H*!NGRDY/OCI4MW8W9OVO;"YABE
MDC$4BS1EU('1A@CD9^E49O#<C6\%JEQ;F*-5 ED@S-&0<DHP(QGWZ4W<2Y3H
M**AM_/$1%QLWACC9_=SQ^.*FIDF;K)-M%;:BGW[*=9,C^X3M8?D?TKM%8,@8
M=",URFH0BXTVZA/\<+C]*VM G-UX?L)B<EX%)^N*PK+6YU4'I8TJ***Q-PK
MOO\ D=M(_P"O6X_FE;]8%]_R.VD?]>MQ_-* -^BBB@ I#]T_2EI#]T_2@##\
M&_\ (IV/T?\ ]#:MVL+P;_R*=C]'_P#0VK=H **** "HIVD15,</FDL 1N P
M.Y_"I:AN 2J_OS#\XY&/FYZ<^M $U%%% !1110 4444 %%%% '/^(?"5CKJ^
M;_Q[WRCY+F,<_1A_$*\TU+3K[1+H6^I1"/<<1S+_ *N3Z'L?8U[74%U9V][
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M ,BG8_1__0VK=H **** "JUX8MD?G3M"/,7!5MNXYX'X^E6:AN&=54I!YQ+
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M,,G Y]N?6I:KW?E;(_-MVF'F+@*F[:<\-^'K0!8HHHH **** "BBB@ HHHH
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M\"6_^)JI14_7:IE[:9;_ .$J\0?] S3O_ EO_B:/^$J\0?\ 0,T[_P "6_\
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M2_\ P*?_ .)H_MSQ-_T#M+_\"G_^)J6BCZQ,/:2(O[<\3?\ 0.TO_P "G_\
MB:/[<\3?] W2_P#P*?\ ^)J7!/048/O1]8F'M)$/]N>)O^@=I?\ X%/_ /$T
M?V]XD7YFTK3G4=52[8,?IE<5-11]8F'M)&OH^L6^LVAEA5XY$;9+#(,/&PZ@
MBM&N*67^R_$5K?+Q#=D6UP.Q/\#?7J/QKM:[*<^>-S:+NKA1115C"L"^_P"1
MVTC_ *];C^:5OU@7W_([:1_UZW'\TH WZ*** "D/W3]*6D/W3]* ,/P;_P B
MG8_1_P#T-JW:PO!O_(IV/T?_ -#:MV@ HHHH *BF,RJODHCG< P9L8'<U+4%
MUY>U/,N&A&]<$,%W'/ _'TH GHHHH **:SJF-[*N3@9.*4G S0 M9FLZ_8:%
M;^;>2_,W$<2<O(?0"L#7_'$=N[V6CA+FZ'#S'_51'Z_Q'V%<0WF37+W5U,]Q
M=/\ >EDZ_0>@]A7+B,7"EINS*I54?4NZQK6H>(7_ -+/D68.4M$;@^[GN?;I
M4=I9O=.40I&B+N9VX5%%059LKM;5Y \?FQ2H4D0-@D>Q]:\>55U9WJ,Y7-R?
MO#CIMPTI2WVW0"[M\)R,?CT/M2RZ9=16\<_EL\;+DE1]WG&#5B+4[:$&-+)E
MA#*Z@2_-N'=CWI?[;?S?,\D;MFW[W&=V<U7+2MJPM J'3;X2",VDN\C<!CM3
M_P"RKI;V&UD"QR3 %<G( ]\59DUI3'+'%;LJR!]VY\G<W7\*A&I*+ZUNA"=T
M*A6&[[V/3TI.-);,+0(KS3WLEC<RQR(Y(#)D<CKP0#4%A>7NC71N=,E$98YD
M@;_5R_4=C[BKFH:D+V*.,1R81BV^63>W/;/I6?2]I[.=Z3#FY97B>D:!XKLM
M<'DG-M?*/GMI#S]5/\0K?KQ62)9"K9970Y21#AD/J#74Z'XXELRMKKAWQ=$O
M5'_H8[?6O5P^,C5TEHSIIUE+1[GH-%,BECFB62)U=&&593D$4^NTV"J6HPF2
M'>.J<_A5PD 9) ^M! (YZ5E6I*K3<'U*C)Q=T><^,].GO-&6ZM0'N;%_M"1.
MNY) .H*_Q<<CW%0Z-K3VU@;F^-TMFPW)<WN$EF<_PQQ 9"^@K2U37%2[EL](
M1+N93AI<_NHOJ>Y]A6;#8XN/M=W,UU>'_EK(.%]E'117SZI.,?9U5M]YK6Q4
M(.\=6$LU[JP9=K:=8,<F-.)9<]V(^Z#Z#FK$$$-M"L,$:QQKT51BI**J]E9:
M(\RI5G4=Y!1112,@HHHH **IW6JV%C,L-U=Q0R. 55SU!.,_GQ36UG34:=6O
M808!F7)^[SC^9Q5<LNP[,O45E2>(]+6VN)HKN.9H87F,:'YB%Z]?>GQZ_I;V
M\4IO(E\QM@4GG?@$K]>:?)+L'*R36#,-)N# 7#@#/E_>VY&['OC-9CW=G80R
M7>DF1[>-E\]%W%"""!C/\62,X_&KDWB'3TMYI;>=;EX653'$>26;:,>HSW'I
M2/JFEW+01W4T2LTQ\E"Y(=E) /'!Y!X/I5Q32U123[&?<7%TT-Q;7=TQN% 4
MVZQ<,,*=^0..<^W&*MZ/>WUUJ$RW,B[1OW1'K&0V%[# QZDYZU=?6M-C17>^
MB560.K$]5)P#^)IL>O:5,CO'?PNJ(';!Z+G&?SXIMNUN4-;;%6PN5%]J<=HW
MVF3S58(\I';#8)[ ]JIWD\7F:M%#<,SL(B1N8A3DAO\ @([X[5?D\2:;'=6\
M37">7/&9%FS\HPP7'US_ "J_<W]K9%1<SI%N&1GT]?I2NT]@V>Q5T,DZ>P)!
M F<*5SL(SQLSSM^M:59\&L07%PR(K>4K;!,67:6Z8QG(Y[XJU#=V]P0(9EDR
M"1M/8'!_6HDG>[1+3)J*9YJ>:(MPWE=P'M3ZD04444@"BBB@ J&ZMUNK:2$\
M;AP?0]C4U%-.SNAIV.J\-:B^IZ'!-+_KDS%+_O+P:SO$Z"'5=*O!W=H&^C#C
M]:A\&R;+S5;7/ D64#TR.:N^,1C2(9>\=S&P_.O>3YZ=^Z.Z_-$@I1U%(>M%
M>><QQWDW[V-S>Q-+$J>=OE-TS&0=@$Z+]:GDMWATVW\UELM[H2)[V1TFXZ,_
M5*Z6>>"UA,D\D<48ZLYP*JP:MI]U%%F:(><"4CD(RP'M5\S*N9RZF8?#,=Q"
MSQ$R>4K.XEQSU#-@%?0FJ-OKVI7%N9UEB_<JF^-8P?,)8J>>WX5T/]J:8T,C
M_;+8Q1X#_,"%]!3AJ&G^:D0NK?S)!E5##+#K1?R Y9=1N;R^5/M0FEGA4&*,
M;?+(8DKQWXQZU9CUK49GMXHKN%C,R;V$(/D$DY3'K@=^:V(]:TZ2Z>**2)MF
M"\H90HS[_A4PU33/*\T7EJ(R^-VX8+?XTV_(+F;J;VW]L-%J=W);VJVVZ$B4
MQ!FR=QR.K#C K)-U*L=O<WETTLHBC_<&=H9EYX9!T<GN#767%Y901QO<SPHC
MGY#(1@GVH6]L9;L0+<0/<KDA 06'K23TV"Y-%+',F^-PRYP2#T(ZCZT^FI&D
M:D(H4$DD =SUIU0(H:W$9=&NMOWXU\U#Z,IW#^5=?8SBZL+>X'22-6'XBN<E
M7S(9$/\ $A'YBM+PG(9/"VG$]H0OY<5UX9Z-&M(V:***ZC4*P+[_ )';2/\
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M,/@XT_>EJSKIT5'5[D<$$5M"D,$:QQ(,*B#  J2BBNTV"BBB@ HHHH ****
M.;UCPE!>3->Z=)]AOSRSJ,QR_P"^O?ZCFN9:>>SNA9:I!]DNC]PDYCE]T;O]
M#S7I55K[3[34K5K:\@2:%NJN/U'H?>N>MAX5=]S.=-2.'HJ34/#^HZ)F2R\S
M4-/')B)S/$/8_P 8]NOUJG;WUM=Q[X)T8=",X*GT(/(->55H3I/4Y90<=R4P
MQ%F8PQEF&&8H,L/0^M'E1^9YGEIO_O;1G\Z7>O\ ?7\Z-Z_WU_.L=2#-NO#V
MG7MW]IG28RY)R)V Z8QC/3VIJ>&],B&(XYT&<_)<..?7@]:U-Z_WU_.C>O\
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MQ?<A0*/?WKG-9E^U^*;>!>4LX3(_^\W _2MC6=?L-$MR]S.GG$?NX PWR'L
M*YK3B$26YN[B#[9=/YDN)!\OHOX"O2KRM&W<Z)NR-*BHOM-O_P _$/\ W\'^
M-'VFW_Y^(?\ OX/\:X+,P&26-G*B)):0.J-N0-&"%/J*@N=%T^Z5PUK$ID=6
MD9$ +X['U%6OM-O_ ,_$/_?P?XT?:;?_ )^(?^_@_P :>H:C/L%EF$_8X/W/
M^J_=C]W]/2B2PLYH_+DM('CQMVM&",=<4_[3;_\ /Q#_ -_!_C1]IM_^?B'_
M +^#_&EJ&HP6-FLL<HM(!)$NV-Q&,J/0>E*]C:27#3O:PM,R[#(8P6*^F?2G
M?:;?_GXA_P"_@_QH^TV__/Q#_P!_!_C1J&I"-*TX$D6%J"1@_NAZ8_E2C3-/
M5F9;&V#,NUCY0Y&,8^E2_:;?_GXA_P"_@_QH^TV__/Q#_P!_!_C3U#46"WAM
M85AMX4BC7HB+@"I*B^TV_P#S\0_]_!_C39+ZSAC,DMW;H@ZLTHP/UI68%760
M9[6*Q3_67LRP@?[.<L?R!KMXU"1J@Z*,"N4\/6SZKJ?]M2QLEK$ICLE<8+9^
M])CWZ#VKK:]"C#ECJ;P5D%%%%:EA6!??\CMI'_7K<?S2M^L"^_Y';2/^O6X_
MFE &_1110 4A^Z?I2TA^Z?I0!A^#?^13L?H__H;5NUA>#?\ D4['Z/\ ^AM6
M[0 4444 %%%% !1110 4444 %%%% !1110 R6&.>)HI462-QAE89!%<#K7@:
M>T=KC0AYD).6LG;&/]QC_(UZ#143IQJ+EDA2BI*S/--*\&:GJ4N[4D;3[,=4
M#@RR>V1PH_6O0;#3K33+1+6S@2&%.BJ/U/J:M44J=*%-6BA1BHJR"BBBM"@H
MHHH **** "BBB@ HHHH **** "LR\\.Z-J$_GW>FVTLIZNT8R?QK3HH P_\
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M4>1KG_/]9?\ @,W_ ,50!JT5E>1KG_/]9?\ @,W_ ,51Y&N?\_UE_P" S?\
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MYGU.U,4\2+/B$;XR2A!W;ASUXKHS+&)1$77S",A<\D5FZK_Q_P"E_P#7P?\
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M6X_FE;]8%]_R.VD?]>MQ_-* -^BBB@ I#]T_2EI#]T_2@##\&_\ (IV/T?\
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MO_KX/_H)K5K*U7_C_P!+_P"O@_\ H)H U:*** "BBB@ HHHH **** "BBB@
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M_BI;-O\ I@XK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6!XML[Z^TZU@L3<
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M/W3]* ,/P;_R*=C]'_\ 0VK=K"\&_P#(IV/T?_T-JW: "BBB@ HHHH ****
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MR>/QK2FM]-U*1EE"O)!\C?,5./0XQD?I27$VE6$;6DY2-)069-I((/!)QT%
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M &=;^)DEALY!;NR7!VB;(5,C /7WZ#J<5N1,SQAGC*,>JDYQ5(Z)IY(_T<
M@E0Q )&,9&<'H/RJW;P+;0+$K,P4<%CDT 2U@7W_ ".VD?\ 7K<?S2M^L"^_
MY';2/^O6X_FE &_1110 4A^Z?I2TAZ&@##\&_P#(IV/T?_T-JW:Y'PWKVDZ9
MH<-A?ZA;VMW;LZ2PS.$93O/8_7K6M_PEGA[_ *#5C_W_ %_QH 9XCL)[VV5X
M(HIO+1P8I,\Y4@$8[BLV'P[?"$F*1(_E\Q"SMDN<$!EZ#&#T]:U?^$L\/?\
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M)]P0?SITWA^]\MHP+>>-R%D$C$$KDDX.#@GIGZUH_P#"6>'O^@U8_P#?]?\
M&C_A+/#W_0:L?^_Z_P"- %&3P_=RS!6%N+<2LX7<22&=&VXQT&TC\JCD\-7*
M1A;<6P5N)%(^]\[D=CT##\L5I?\ "6>'O^@U8_\ ?]?\:/\ A+/#W_0:L?\
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M_9]E_P ^=O\ ]^E_PJS10!6_L^R_Y\[?_OTO^%']GV7_ #YV_P#WZ7_"K-%
M%;^S[+_GSM_^_2_X4?V?9?\ /G;_ /?I?\*LT4 5O[/LO^?.W_[]+_A1_9]E
M_P ^=O\ ]^E_PJS10!6_L^R_Y\[?_OTO^%']GV7_ #YV_P#WZ7_"K-% %;^S
M[+_GSM_^_2_X4?V?9?\ /G;_ /?I?\*LT4 5O[/LO^?.W_[]+_A1_9]E_P ^
M=O\ ]^E_PJS10!6_L^R_Y\[?_OTO^%']GV7_ #YV_P#WZ7_"K-% %;^S[+_G
MSM_^_2_X4?V?9?\ /G;_ /?I?\*LT4 5O[/LO^?.W_[]+_A1_9]E_P ^=O\
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..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
